ALPS Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

ALPS Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$782K	Buy	2,475 +35	+1%	+$8.25K	﹤0.01%	766
2026 Q1	$487K	Buy	+2,440	New	+$483K	﹤0.01%	871
2022 Q4	–	Sell	-14,810	Closed	-$796K	–	1065
2022 Q3	$796K	Sell	14,810 -1,231	-8%	-$72.4K	0.01%	512
2022 Q2	$893K	Sell	16,041 -11,729	-42%	-$666K	0.01%	498
2022 Q1	$1.95M	Sell	27,770 -3,232	-10%	-$234K	0.02%	214
2021 Q4	$2.99M	Sell	31,002 -1,754	-5%	-$162K	0.03%	196
2021 Q3	$2.85M	Sell	32,756 -2,228	-6%	-$172K	0.03%	226
2021 Q2	$2.86M	Sell	34,984 -11,639	-25%	-$968K	0.03%	225
2021 Q1	$4.43M	Buy	46,623 +40	+0.1%	+$3.78K	0.04%	185
2020 Q4	$2.89M	Buy	46,583 +13,721	+42%	+$782K	0.03%	220
2020 Q3	$1.95M	Sell	32,862 -2,240	-6%	-$153K	0.03%	239
2020 Q2	$2.45M	Sell	35,102 -13,006	-27%	-$825K	0.03%	217
2020 Q1	$2.18M	Sell	48,108 -8,561	-15%	-$485K	0.03%	206
2019 Q4	$3.69M	Sell	56,669 -4,130	-7%	-$276K	0.03%	180
2019 Q3	$3.77M	Sell	60,799 -10,105	-14%	-$634K	0.03%	169
2019 Q2	$5.05M	Sell	70,904 -13,954	-16%	-$1.03M	0.04%	155
2019 Q1	$6.66M	Buy	84,858 +3,350	+4%	+$254K	0.05%	143
2018 Q4	$6.9M	Buy	81,508 +18,741	+30%	+$2M	0.05%	135
2018 Q3	$10.7M	Buy	62,767 +13,420	+27%	+$2.02M	0.07%	119
2018 Q2	$6.38M	Buy	49,347 +3,974	+9%	+$443K	0.04%	149
2018 Q1	$4.67M	Buy	45,373 +7,885	+21%	+$780K	0.04%	153
2017 Q4	$3.2M	Buy	37,488 +4,461	+14%	+$387K	0.02%	161
2017 Q3	$2.81M	Buy	33,027 +2,758	+9%	+$218K	0.02%	169
2017 Q2	$2.29M	Buy	30,269 +1,510	+5%	+$106K	0.02%	175
2017 Q1	$1.9M	Sell	28,759 -3,436	-11%	-$226K	0.01%	181
2016 Q4	$2.04M	Sell	32,195 -10,422	-24%	-$658K	0.02%	178
2016 Q3	$2.71M	Sell	42,617 -10,795	-20%	-$793K	0.02%	167
2016 Q2	$3.97M	Buy	53,412 +10,492	+24%	+$779K	0.04%	135
2016 Q1	$2.87M	Sell	42,920 -7,244	-14%	-$440K	0.03%	136
2015 Q4	$3.39M	Sell	50,164 -7,900	-14%	-$488K	0.03%	145
2015 Q3	$3.1M	Buy	58,064 +15,342	+36%	+$931K	0.03%	139
2015 Q2	$2.69M	Buy	42,722 +15,747	+58%	+$859K	0.02%	147
2015 Q1	$1.3M	Buy	+26,975	New	+$1.03M	0.01%	172
2014 Q1	–	Sell	-16,822	Closed	-$650K	–	642
2013 Q4	$650K	Buy	16,822 +8,191	+95%	+$267K	0.01%	170
2013 Q3	$233K	Buy	+8,631	New	+$243K	﹤0.01%	583

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's LGND Position: Q2 2026 in Review

ALPS Advisors increased its Ligand Pharmaceuticals (LGND) stake by 1.4% in Q2 2026, buying an estimated $8.25K and bringing the position to 2,475 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #766.

ALPS Advisors first reported a position in LGND in Q3 2013 and has held it in 35 quarters since. The position peaked at $10.7M in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

ALPS Advisors held 2,475 shares of Ligand Pharmaceuticals worth $782K as of Q2 2026.
ALPS Advisors bought 35 Ligand Pharmaceuticals shares in Q2 2026, an estimated $8.25K.
Ligand Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #766 holding.
ALPS Advisors first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 35 quarters since.
ALPS Advisors's Ligand Pharmaceuticals position peaked at $10.7M in Q3 2018.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.